Based on our national registry, BEST1-related diseases accounted for 0.21% of IRD patients, 6.8% of macular dystrophy patients, and 40.9% of bestrophinopathy patients (with PRPH2 representing 7.1% of these patients). This evidence concerns the gene PRPH2 and Macular dystrophy.